In medical news, patients’ advocates have launched legal challenges to patents on hepatitis C drugs in India and Argentina, saying pharmaceutical companies are profiting from monopoly prices that leave millions unable to afford life-saving medications. In a statement, Médecins Sans Frontières, or Doctors Without Borders, said, “There are 80 million people worldwide living with hepatitis C, and we need a wide range of combination treatments available at an affordable price. With patents blocking generic competition, treatment remains prohibitively expensive in many countries.”